Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Coutinho Coelho (Brasília, Brazil), K. Smidt Simon (Brasília, Brazil), C. Augusto Melo-Silva (Brasília, Brazil), P. De Holanda Veloso Junior (Brasília, Brazil), J. Figueiró Longo (Brasília, Brazil), L. Maciel Sousa Vianna (Brasília, Brazil), V. Moreira Amado (Brasília, Brazil), M. Renata Mortari (Brasília, Brazil), A. Lorenzetti Bocca (Brasília, Brazil). The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis.. 4741

Member's Comments

No comment yet.

Related content which might interest you: The role of antimicrobial peptides in cystic fibrosis in childhood. Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010 αB-crystallin is involved in the process of pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 αB-crystallin is involved in the process of pulmonary fibrosis Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 The role of viruses in the pathogenesis of pulmonary fibrosis Source: Virtual Congress 2021 – Viral infections trigger chronic lung damage and disease Year: 2021 Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis Source: Eur Respir J, 57 (4) 2000652; 10.1183/13993003.00652-2020 Year: 2021 Possible target genes in idiopathic pulmonary fibrosis Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases Year: 2007 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 The role of systemic markers of inflammation in bronchiectasis. Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 Increased endothelial and epithelial apoptosis play a central role in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Low telomerase expression in alveolar epithelial plays a role in the pathogenesis of idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Dysregulation of the expression and activity of antimicrobial peptides in COPD and cystic fibrosis Source: International Congress 2018 – Antimicrobial host defence and innate immunity in the lung Year: 2018 The lung epithelium is a prominent source of Wnt ligands and inhibitors in idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon Year: 2008 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013